Verastem Oncology secures collaboration with GenFleet Therapeutics, potentially worth up to $600M+

Verastem Oncology inked a deal potentially worth up to $625.5 million with Chinese biotech GenFleet Therapeutics that aims to move three oncology programs into the clinic.

Verastem will pay GenFleet $11.5 million for one program, though the deal size for all three programs is worth up to $625.5 million, excluding royalties. The deal will also give GenFleet the development and commercial rights to those three candidates in China, while Verastem would get the rights for the drugs everywhere else.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Talkspace Appoints New Chief Medical Officer – Executive Hires

Nikole Benders-Hadi, MD, Chief Medical Officer at Talkspace What You Should Know: – Talkspace, an online behavioral health company, announced the appointment of Nikole Benders-Hadi,

October 26, 2023

Novel Antibody for Chronic Hives Brings Relief in Mid-Stage Trial

WASHINGTON — Barzolvolimab, a first-in-class anti-KIT monoclonal antibody, reduced the severity of hives in adults with chronic spontaneous urticaria (CSU) who remained symptomatic on antihistamines,

February 29, 2024

BC Helps Drive Canadian Cannabis Sales Higher in April

Statistics Canada released April retail sales for the country, with cannabis sales rising from the March levels, up 1.3% to C$411.7 million. March was revised slightly higher

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.